Navigation Links
Ruxolinitib better at reducing myelofibrosis symptoms, study shows
Date:12/12/2011

SAN DIEGO -- In a major advance in treatment, a multicenter study found that ruxolinitib did a better job than off-label chemotherapy drugs reducing the terrible symptoms associated with myelofibrosis, including pain, enlarged spleen, anemia, fever, chills, fatigue, and weight loss. The results were presented today at the annual meeting of the American Society of Hematology and Oncology in San Diego.

Myelofibrosis is a bone marrow disorder that disrupts the body's normal production of blood cells, resulting in extensive scarring in the bone marrow. Patients tend to be over age 50.

"For years, researchers have struggled to find effective medications to help patients struggling with symptoms of this chronic pre-leukemia condition," says lead investigator Ruben Mesa, M.D., of Mayo Clinic in Arizona. There are several thousand new myelofibrosis patients in the U.S. every year.

Only about 10 percent of myelofibrosis patients are eligible for a bone marrow transplant and chemotherapy often falls short, Dr. Mesa says. A handful of off-label chemotherapy drugs have been modestly helpful, he says.

A randomized, double-blind clinical trial, known as the COMFORT-1 study, showed that ruxolinitib reduced spleen size by more than 35 percent in almost all of the 154 patients studied. An enlarged spleen, caused by sequestered over-proliferating blood cells, causes discomfort and can also lead to the need for blood transfusions and further medical complications for patients.

In the study, patients treated with ruxolinitib also reported less severe symptoms than those reported by patients treated with a placebo.

A tandem randomized investigation in Europe, known as the COMFORT-2 study, showed that ruxolinitib also was more effective at reducing symptoms than the best available chemotherapies -- specifically, the off-label drugs doctors have been offering.

"The studies confirmed the drug is very effective. As a representative of a particular class of molecular inhibitors called JAK2 inhibitors, which are now being widely studied, ruxolinitib suggests this category will continue to be promising for myelofibrosis," Dr. Mesa says. Most surprising for researchers, however, was the ultimate comparison between the two clinical trials.

"When we looked at the control arms of the two studies we found that the best available chemotherapies we've been using up to this time are no more effective than a placebo," Dr. Mesa says. The comparison provided a wake-up call, he adds. "This was a unique piece of information we hadn't had in the past, and it offers further incentive and pressure to find better therapies for patients."


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Autism-Related Hypersensitivity Better Understood
2. Developing guidelines for better reporting of health research
3. Hawaiian-shirt.net Offers 10 Tips To Beat The Winter Blues: Things You Can Do Right Now to Have a Better Day
4. Better care at any hour for palliative patients
5. Patients Do Better at Hospitals That Follow Stroke Guidelines
6. More Expensive Hospital Care May Not Mean Better
7. New MRI May Lead to Better Brain Pictures
8. Biological clock could be a key to better health, longer life
9. Why do physicians order costly CTs? Ultrasound yields better diagnosis, safer, less costly
10. BetterInvesting Magazine Releases May Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
11. New approach to immune cell analysis seen as first step to better distinguish health and disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... ... affiliations and de novo development, today announced Cumberland Skin Surgery and Dermatology ... Surgery and Dermatology, with offices in both Hermitage and Lebanon, Tennessee, provides comprehensive ...
(Date:8/16/2017)... ... 2017 , ... Paul Vitenas, MD, FACS , is honored to announce ... list identifies the nation’s top physicians, in a variety of specialties. This marks the ... of Castle Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of ... every reprocessing cycle, both between patient procedures and before storage, is a requisite ... as important to the prevention of disease transmission and nosocomial infection as cleaning ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... $5.99, eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery ... of God's love, and all the many ways God shows love to those ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... an opportunity for men and women to train as hospice volunteers. Volunteers provide ... life-limiting illness. For over 30 years, the agency has trained volunteers to be ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... Tenn. , July 31, 2017 Three Tru-D SmartUVC ... Yongsan, South Korea . Tru-D, short for "Total Room ... and operating rooms after an environmental services (ES) professional cleans the area ... ... "Although the ...
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
(Date:7/27/2017)... WARSAW, Ind., July 27, 2017  Zimmer Biomet Holdings, ... the quarter ended June 30, 2017.  The Company reported ... of 1.1% over the prior year period, and an ... approximately 240 basis points of contribution from the LDR ... from the second quarter of 2016, or 0.3% on ...
Breaking Medicine Technology: